16.35
-0.41 (-2.45%)
| 前收盘价格 | 16.76 |
| 收盘价格 | 16.81 |
| 成交量 | 295,661 |
| 平均成交量 (3个月) | 446,104 |
| 市值 | 5,839,651,840 |
| 预期市盈率 (P/E Forward) | 14.95 |
| 价格/销量 (P/S) | 1.13 |
| 股市价格/股市净资产 (P/B) | 0.950 |
| 52周波幅 | |
| 利润日期 | 28 Oct 2026 |
| 营业毛利率 | -7.50% |
| 营业利益率 (TTM) | -5.36% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | 3.50% |
| 总债务/股东权益 (D/E MRQ) | 75.07% |
| 流动比率 (MRQ) | 1.56 |
| 营业现金流 (OCF TTM) | 166.00 M |
| 杠杆自由现金流 (LFCF TTM) | 69.00 M |
| 资产报酬率 (ROA TTM) | 0.61% |
| 股东权益报酬率 (ROE TTM) | -5.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看涨 | 混合的 | |
| 股票 | Bausch + Lomb Corporation | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 1.0 |
| 平均 | 0.00 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Core |
| 内部持股比例 | 88.13% |
| 机构持股比例 | 10.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Silver Point Capital L.P. | 31 Mar 2026 | 2,245,000 |
| Clark Estates Inc/Ny | 30 Jun 2026 | 881,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合